Generation Bio Co.

Equities

GBIO

US37148K1007

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-27 pm EST 5-day change 1st Jan Change
2.36 USD +6.79% Intraday chart for Generation Bio Co. +19.80% +43.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Generation Bio Co.(NasdaqGS:GBIO) dropped from NASDAQ Biotechnology Index CI
Generation Bio Insider Bought Shares Worth $124,778, According to a Recent SEC Filing MT
Wedbush Adjusts Generation Bio Price Target to $5 From $9, Maintains Outperform Rating MT
Generation Bio to Lay Off 40% of Staff in Bid to Extend Cash Runway Into H2 2027 MT
Generation Bio Co. Announces Termination of Executives, Effective on January 28, 2024 CI
Wedbush Lowers Generation Bio's Price Target to $9 From $11, Maintains Outperform Rating MT
Generation Bio Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Generation Bio Co. Announces Demonstration of Highly Selective T Cell Transduction in Vivo with Cell-Targeted Lnp Platform CI
North American Morning Briefing : Yields Fall -2- DJ
JMP Securities Downgrades Generation Bio to Market Perform From Market Outperform MT
North American Morning Briefing : Bond Yields, -2- DJ
TD Cowen Downgrades Generation Bio to Market Perform From Outperform MT
Generation Bio Co. Announces Breakthrough in Its Non-Viral Genetic Medicine Platform with Novel "Immune-Quiet" Dna CI
Generation Bio Sank 10% in After-Hours Thursday, Setting Stage for Fourth Straight Day of Losses in Regular Trading Friday MT
JPMorgan Chase Adjusts Price Target on Generation Bio to $9 From $8, Maintains Neutral Rating MT
Generation Bio Co. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Generation Bio Co. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Generation Bio Co., Appoints Yalonda Howze, J.D., as Chief Legal Officer and Secretary CI
Sector Update: Health Care Stocks Mixed During Late Afternoon MT
Wedbush Cuts Generation Bio's Price Target to $11 From $15, Maintains Outperform Rating MT
Moderna, Generation Bio Working Together to Develop Non-Viral Genetic Medicines MT
Generation Bio, Moderna Enter Collaboration to Accelerate Non-Viral Genetic-Medicines Pipeline DJ
Moderna, Inc. and Generation Bio Co. Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines CI
Generation Bio Co. announced that it expects to receive $36 million in funding from Moderna, Inc. CI
Needham Adjusts Price Target on Generation Bio to $14 From $23, Maintains Buy Rating MT
Chart Generation Bio Co.
More charts
Generation Bio Co. develops genetic medicines to provide treatments for rare and prevalent diseases. The Company through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. Its platform is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. It has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.36 USD
Average target price
8.25 USD
Spread / Average Target
+249.58%
Consensus
  1. Stock
  2. Equities
  3. Stock Generation Bio Co. - Nasdaq
  4. News Generation Bio Co.
  5. Generation Bio to Lay Off 40% of Staff in Bid to Extend Cash Runway Into H2 2027
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW